Crysvita dosing update approved for XLH

What this means

Crysvita is an antibody treatment that targets a protein causing low phosphate levels in people with X-linked hypophosphatemia, a rare genetic bone disorder. The FDA has approved updated dosing instructions for Crysvita in adults with this condition. This change could help doctors better tailor treatment for patients, potentially improving symptom management and quality of life.